Deutsche Bank AG Has $106,000 Stock Holdings in Elevation Oncology, Inc. (NASDAQ:ELEV)

Deutsche Bank AG grew its holdings in Elevation Oncology, Inc. (NASDAQ:ELEV) by 550.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 188,771 shares of the company’s stock after purchasing an additional 159,751 shares during the period. Deutsche Bank AG owned approximately 0.32% of Elevation Oncology worth $106,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of ELEV. JPMorgan Chase & Co. grew its position in Elevation Oncology by 175.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 61,334 shares of the company’s stock worth $37,000 after acquiring an additional 39,101 shares during the last quarter. SG Americas Securities LLC raised its stake in Elevation Oncology by 33.9% during the 4th quarter. SG Americas Securities LLC now owns 61,467 shares of the company’s stock worth $35,000 after buying an additional 15,560 shares during the period. Palumbo Wealth Management LLC increased its holdings in Elevation Oncology by 294.5% during the 4th quarter. Palumbo Wealth Management LLC now owns 69,105 shares of the company’s stock worth $39,000 after purchasing an additional 51,590 shares in the last quarter. Virtu Financial LLC bought a new stake in Elevation Oncology during the 4th quarter worth approximately $36,000. Finally, Geode Capital Management LLC increased its holdings in Elevation Oncology by 4.3% during the 4th quarter. Geode Capital Management LLC now owns 1,157,572 shares of the company’s stock worth $651,000 after purchasing an additional 47,487 shares in the last quarter. Institutional investors own 83.70% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on ELEV. Stephens reiterated an “equal weight” rating and issued a $1.00 price objective (down previously from $5.00) on shares of Elevation Oncology in a research note on Monday, March 24th. Leerink Partnrs downgraded Elevation Oncology from a “strong-buy” rating to a “hold” rating in a research report on Thursday, March 20th. Wedbush cut Elevation Oncology from a “strong-buy” rating to a “hold” rating in a research note on Thursday, March 20th. Citigroup cut Elevation Oncology to a “market perform” rating in a research note on Friday, March 21st. Finally, William Blair reaffirmed an “outperform” rating and set a $5.00 price objective on shares of Elevation Oncology in a research note on Friday, March 7th. Seven analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $3.39.

Elevation Oncology Trading Down 2.1%

NASDAQ:ELEV opened at $0.30 on Wednesday. The company has a current ratio of 17.77, a quick ratio of 17.77 and a debt-to-equity ratio of 0.45. Elevation Oncology, Inc. has a 12 month low of $0.22 and a 12 month high of $3.84. The company has a market cap of $18.06 million, a PE ratio of -0.37 and a beta of 1.59. The company has a 50 day simple moving average of $0.32 and a two-hundred day simple moving average of $0.50.

Elevation Oncology (NASDAQ:ELEV) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). Research analysts forecast that Elevation Oncology, Inc. will post -0.84 earnings per share for the current year.

Elevation Oncology Company Profile

Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.